ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...

Thoratec Corp. THOR recently announced the start of patient enrollment in the SHIELD II U.S. clinical trial, which aims at exploring the use of HeartMate PHP in patients undergoing high-risk ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...

Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...

Good news for the HeartMate 3 (Abbott Cardiovascular) as a bridge to heart transplantation: in the 2 years following US Food and Drug Administration approval of the left ventricular assist device ...

Abbott is recalling a system monitor used with the Heartmate cardiac pump because screen display issues could pose a risk to patients. The Class 1 recall affects 4,842 monitors distributed in the U.S.

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

Cleveland, OH - Patients implanted with a HeartMate II (Thoratec) left ventricular assist device (LVAD) following its 2008 FDA approval have had similar outcomes to what was predicted by the ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

Please provide your email address to receive an email when new articles are posted on . A new bridge-to-transplant technology is now available for patients in need of a left ventricular assist device.

Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced results from the HeartMate 3 CE Mark trial. HeartMate 3 met the ...

Thoratec Corp.THOR recently announced the start of patient enrollment in the SHIELD II U.S. clinical trial, which aims at exploring the use of HeartMate PHP in patients undergoing high-risk ...